Showing results (181-190 of 201) with videos related to
Sort By:
Pageof 21
Research Square|February 6, 2026
Contextual variability in under-diagnosed cardiometabolic disease and cognitive vulnerability among populations at high risk for Alzheimer's disease and related dementiasNwanyieze Jiakponnah, Joseph Curran, Tamlyn Watermeyer, et al.The New Phytologist|May 26, 2025
At-RS31 orchestrates hierarchical cross-regulation of splicing factors and integrates alternative splicing with TOR-ABA pathwaysTino Köster, Peter Venhuizen, Martin Lewinski, et al.The Journal of Molecular Diagnostics : JMD|May 13, 2022
RNA-Based Targeted Gene Sequencing Improves the Diagnostic Yield of Mutant Detection in Chronic Myeloid LeukemiaNaranie Shanmuganathan, Carol Wadham, Daniel Thomson, et al.International Journal of Hematology|May 19, 2009
A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALLArinobu Tojo, Kensuke Usuki, Akio Urabe, et al.Cancer|April 8, 2017
Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutationFranck E Nicolini, Grzegorz W Basak, Dong-Wook Kim, et al.Blood|March 9, 2006
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing resultsTimothy Hughes, Michael Deininger, Andreas Hochhaus, et al.Research Square|July 28, 2023
Multi-ancestry epigenome-wide analyses identify methylated sites associated with aortic augmentation index in TOPMed MESAAni Manichaikul, Xiaowei Hu, Jeongok Logan, et al.Hypertension (Dallas, Tex. : 1979)|February 11, 2026
Factors Associated With Discordant Blood Pressure Measures among Very Old Adults: Results From the Atherosclerosis Risk in Communities (ARIC) StudyFredrick Larbi Kwapong, Benjamin Grobman, Hannah Col, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 11, 2008
Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemiaNeil P Shah, Hagop M Kantarjian, Dong-Wook Kim, et al.British Journal of Haematology|December 23, 2025
The PINNACLE study: A multicentre phase II trial of nilotinib in combination with pegylated interferon-α2b in newly diagnosed chronic phase chronic myeloid leukaemiaDavid T Yeung, Andrew P Grigg, John Reynolds, et al.Pageof 21